Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aytu Biopharma Inc AYTU

Healthcare
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended... see more

Recent & Breaking News (NDAQ:AYTU)

Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter

Accesswire November 23, 2021

Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)

Accesswire November 17, 2021

Aytu BioPharma Reports First Quarter 2022 Financial Results

Accesswire November 15, 2021

Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021

Accesswire November 8, 2021

ALERT: Rowley Law PLLC is Investigating Potential Breaches of Fiduciary Duty by the Aytu BioPharma, Inc. Board of Directors

PR Newswire October 4, 2021

CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences

Accesswire September 30, 2021

Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results

Accesswire September 27, 2021

Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021

Accesswire September 23, 2021

Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome

Accesswire September 9, 2021

Aytu BioPharma to Present at Upcoming September Investor Conferences

Accesswire September 7, 2021

Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus

Accesswire July 27, 2021

Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study

Accesswire June 28, 2021

Aytu BioPharma to Present at Upcoming June Investor Conferences

Accesswire May 25, 2021

Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

Accesswire May 17, 2021

Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells

Accesswire May 12, 2021

Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021

Accesswire May 10, 2021

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

Accesswire April 12, 2021

Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer

Accesswire April 5, 2021

Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma

Accesswire April 1, 2021

Aytu BioScience Announces Close of Merger with Neos Therapeutics

Accesswire March 22, 2021